$ETON News
Last published 6d ago
- 6d agoETONEton Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoETONEton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswireRecord Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of scheduleQ3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully
- 6d agoETONEton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswireRecord Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of...
- 6d agoETONEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal TolerabilityGlobeNewswireTreatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN® participantsHepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11%
- 1w agoETONEton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireDEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing
- 1w agoAQSTETONAquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAnaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if
- 1w agoETONEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic SpasmsGlobeNewswireET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1)
- 1w agoETONEton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswireDEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing
- 4w agoETONAQSTEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmGlobeNewswireDifferentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient
- 2mo agoETONEton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare ConferenceGlobeNewswireDEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing
- 3mo agoETONEton Pharmaceuticals Reports Second Quarter 2026 Financial ResultsGlobeNewswireRecord revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA
- 3mo agoETONEton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001GlobeNewswireASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride) oral solution,
- 3mo agoETONEton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026GlobeNewswireDEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing
- 3mo agoETONEton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral SolutionGlobeNewswireFDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency marketNew formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE®Submission allows for a
- 5mo agoETONEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)GlobeNewswireIMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening parasitic
- 6mo agoETONEton Pharmaceuticals Q1 2026 Earnings Call - ETON PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and welcome to the E&M Pharmaceuticals first quarter 2026 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up
- 6mo agoETONEton Pharmaceuticals Reports First Quarter 2026 Financial ResultsGlobeNewswireQ1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 millionQ1 2026 fully
- 6mo agoETONEton Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireDEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 6mo agoETONEton Pharmaceuticals Q3 2026 Earnings Call - ETON PHARMACEUTICALS INCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 6mo agoETONEton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026GlobeNewswireDEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 6mo agoETONEton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy DistributionGlobeNewswireHEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially
- 6mo agoETONEton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700GlobeNewswireDEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 6mo agoETONEton Pharmaceuticals Announces CFO Succession PlanGlobeNewswireDEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 7mo agoETONETON PHARMACEUTICALS Q4 2025 EARNINGS CALL - ETON PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon and welcome to the Eaton Pharmaceuticals 4th Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up
- 8mo agoETONEton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026GlobeNewswireDEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 8mo agoETONEton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral SolutionGlobeNewswireHEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company's Eton Cares™ patient support
- 8mo agoETONEton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral SolutionGlobeNewswireDESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all
- 8mo agoETONApproval of Desmoda, Nda #219873 (Type 3 - New Dosage Form)FDA Approved DrugsApproval Date: 02/25/2026; Drug Name: Desmoda, Nda #219873; Active Ingredients: DESMOPRESSIN ACETATE; Company: Eton Pharmaceuticals Inc; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form; Application Number: 219873
- 8mo agoETONEton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11thGlobeNewswireDEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 9mo agoETONEton Pharmaceuticals Announces Licensing of Rare Disease Product CandidateGlobeNewswireProduct is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative
- 11mo agoETONEton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4thGlobeNewswireDEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 12mo agoETONEton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18thGlobeNewswireDEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Reports Third Quarter 2025 Financial ResultsGlobeNewswireQ3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS
- 1y agoETONEton Pharmaceuticals Q3 2025 Earnings Call - ETON PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and welcome to the Eaton Pharmaceuticals third quarter 2025 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call u
- 1y agoETONEton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewswireDEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare ConferenceGlobeNewswireDEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoETONEton Pharmaceuticals Reports Second Quarter 2025 Financial ResultsGlobeNewswireQ2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted
- 1y agoETONEton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025GlobeNewswireDEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)GlobeNewswire- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company")
- 1y agoETONEton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® IndexesGlobeNewswireDEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral SolutionGlobeNewswire• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral
- 1y agoETONEton Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswireDEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Reports First Quarter 2025 Financial ResultsGlobeNewswireQ1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of
- 1y agoETONEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025GlobeNewswireDEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)GlobeNewswire- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton
- 1y agoETONEton Pharmaceuticals Out-Licenses International Rights to Increlex®GlobeNewswireDEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
- 1y agoETONEton Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsGlobeNewswireManagement to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential
- 1y agoETONEton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600GlobeNewswire- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE)
- 1y agoETONEton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025GlobeNewswireDEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for